Prescriber Based, Post Marketing Surveillance Study (PMS) to generate safety and efficacy data of Desvenlafaxine and Clonazepam tablets

Akums Drugs and Pharmaceuticals Limited0 个研究点目标入组 200 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients of either sex of age 18 to 60 years [both inclusive]
•2.Willing to give written informed consent
•3.All patients clinically manifesting with symptoms of major depressive disorder

•1)Patients known, or thought to be hypersensitivity to study drug
•2)History of auto-immune disease
•3)Concurrent use of corticosteroids
•4)Any medication or indication that might point to an increased risk, associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the study personnel, would make the subject inappropriate for inclusion
•5)Participation in other clinical trials the last three months and during study participation
•6)Patients with history of epilepsy, or those at risk for seizures or taking seizure drugs
•7)Pregnant, lactating women or women of childbearing age who are not using an acceptable method of birth control
•8)Patients with galactose or fructose intolerance
•9)Patients with severe renal impairment, including those receiving dialysis.
•10)Patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities.
•11)Patients with preexisting gallbladder disease
•12)Active peptic ulcer disease

发起方